Research Analysts Issue Forecasts for Entrada Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:TRDA)

Entrada Therapeutics, Inc. (NASDAQ:TRDA) – Investment analysts at HC Wainwright lowered their Q3 2024 EPS estimates for Entrada Therapeutics in a note issued to investors on Wednesday, August 14th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($0.47) per share for the quarter, down from their prior forecast of ($0.23). HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for Entrada Therapeutics’ current full-year earnings is ($0.13) per share. HC Wainwright also issued estimates for Entrada Therapeutics’ Q4 2024 earnings at ($0.67) EPS, FY2024 earnings at $0.88 EPS, Q1 2025 earnings at ($0.86) EPS, Q2 2025 earnings at ($0.91) EPS, Q3 2025 earnings at ($0.94) EPS and FY2025 earnings at ($3.74) EPS.

Entrada Therapeutics (NASDAQ:TRDA) last posted its quarterly earnings results on Tuesday, August 13th. The company reported $1.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.90. Entrada Therapeutics had a return on equity of 41.31% and a net margin of 43.63%. The business had revenue of $94.69 million during the quarter, compared to analyst estimates of $55.00 million.

Entrada Therapeutics Stock Up 1.7 %

Shares of NASDAQ:TRDA opened at $16.53 on Friday. Entrada Therapeutics has a 52-week low of $10.75 and a 52-week high of $18.17. The business has a fifty day moving average of $15.58 and a two-hundred day moving average of $14.43. The stock has a market cap of $614.92 million, a P/E ratio of 26.24 and a beta of -0.25.

Insiders Place Their Bets

In other news, CFO Kory James Wentworth sold 1,758 shares of the stock in a transaction that occurred on Monday, July 8th. The shares were sold at an average price of $14.95, for a total value of $26,282.10. Following the completion of the sale, the chief financial officer now owns 81,412 shares of the company’s stock, valued at approximately $1,217,109.40. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other Entrada Therapeutics news, CFO Kory James Wentworth sold 1,758 shares of Entrada Therapeutics stock in a transaction on Monday, July 8th. The stock was sold at an average price of $14.95, for a total value of $26,282.10. Following the sale, the chief financial officer now owns 81,412 shares in the company, valued at $1,217,109.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Dipal Doshi sold 1,600 shares of the company’s stock in a transaction on Monday, July 15th. The shares were sold at an average price of $17.81, for a total value of $28,496.00. Following the completion of the transaction, the chief executive officer now directly owns 334,475 shares in the company, valued at approximately $5,956,999.75. The disclosure for this sale can be found here. Insiders have sold 15,571 shares of company stock valued at $245,595 over the last ninety days. Company insiders own 7.58% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. New York State Teachers Retirement System purchased a new stake in shares of Entrada Therapeutics in the 1st quarter valued at approximately $27,000. Acadian Asset Management LLC purchased a new stake in Entrada Therapeutics in the first quarter valued at approximately $79,000. Allspring Global Investments Holdings LLC lifted its stake in Entrada Therapeutics by 427.6% during the first quarter. Allspring Global Investments Holdings LLC now owns 14,763 shares of the company’s stock worth $209,000 after purchasing an additional 11,965 shares in the last quarter. Strs Ohio boosted its position in shares of Entrada Therapeutics by 792.6% during the fourth quarter. Strs Ohio now owns 24,100 shares of the company’s stock worth $363,000 after buying an additional 21,400 shares during the period. Finally, Rhumbline Advisers grew its stake in shares of Entrada Therapeutics by 25.3% in the second quarter. Rhumbline Advisers now owns 36,940 shares of the company’s stock valued at $526,000 after buying an additional 7,452 shares in the last quarter. Hedge funds and other institutional investors own 86.39% of the company’s stock.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.